Usability, Perceived Usefulness, and Shared Decision-Making Features of the AFib 2gether Mobile App: Protocol for a Single-Arm Intervention Study.
Usability, Perceived Usefulness, and Shared Decision-Making Features of the AFib 2gether Mobile App: Protocol for a Single-Arm Intervention Study.
复制标题
DOI：
10.2196/21986
复制
发表时间：
2021-02-24
影响因子：
1.7
通讯作者：
McManus D
中科院分区：
文献类型：
--
作者：
Kapoor A;Andrade A;Hayes A;Mazor K;Possidente C;Nolen K;Hegeman-Dingle R;McManus D
疾病控制和预防中心估计，心房颤动（AF）影响美国270万至610万人。房颤患者往往比其他人有更高的中风风险。虽然大多数房颤患者从抗凝治疗中获益，但绝大多数人对开始抗凝治疗犹豫不决。此外，提供者通常难以帮助患者协商开始抗凝治疗的决定。为了帮助患者和提供者之间关于AC治疗的偏好和知识的沟通，正在使用不同的策略来尝试和解决这个问题。在这项研究中，我们将让患者和提供者使用AFib 2gether应用程序，希望它将创建一个平台，用于在接受AC治疗的AF患者中预防卒中。我们研究的目的是测量使用AFib 2gether的患者与其心脏病提供者之间的接触相关的几种结局。这些结果包括从患者和提供者的角度来看应用程序的可用性和感知有用性。此外，我们将评估共同决策的程度和性质。合格的患者和医疗服务提供者将评估AFib 2gether移动的应用程序的可用性和感知有用性，以促进关于了解患者卒中风险和是否开始AC治疗的共同决策。患者和提供者都将审查该应用程序并完成有关该移动的应用程序在临床环境中的可用性和感知有用性的多个调查问卷。我们还将录音的一个子集的遭遇，以评估共同决策的证据。AFib 2gether共享决策研究的患者和提供者招募仍在进行中。第一名参与者于2019年11月22日入组。结果的分析和发布预计将于2021年春季完成。AFib 2gether应用程序的出现是为了提高患者和提供者参与了解中风和AC治疗风险的共同决策的能力。我们预计AFib 2gether移动的应用程序将促进患者与心脏病专家和其他提供者的讨论。此外，我们希望这项研究将帮助我们确定提供者在将患者置于AC治疗时面临的障碍。我们的目标是展示该应用程序的可用性和感知有用性，未来的目标是在全国多个医疗中心的患者和提供者的更大样本中测试我们方法的价值。ClinicalTrials.gov NCT04118270; https://clinicaltrials.gov/ct2/show/NCT04118270 DERR 1 -10.2196/21986
The Centers for Disease Control and Prevention has estimated that atrial fibrillation (AF) affects between 2.7 million and 6.1 million people in the United States. Those who have AF tend to have a much higher stroke risk than others. Although most individuals with AF benefit from anticoagulation (AC) therapy, a significant majority are hesitant to start it. To add, providers often struggle in helping patients negotiate the decision to start AC therapy. To assist in the communication between patients and providers regarding preferences and knowledge about AC therapy, different strategies are being used to try and solve this problem. In this research study, we will have patients and providers utilize the AFib 2gether app with hopes that it will create a platform for shared decision making regarding the prevention of stroke in patients with AF receiving AC therapy. The aim of our study is to measure several outcomes related to encounters between patients and their cardiology providers where AFib 2gether is used. These outcomes include usability and perceived usefulness of the app from the perspective of patients and providers. In addition, we will assess the extent and nature of shared decision making. Eligible patients and providers will evaluate the AFib 2gether mobile app for usability and perceived usefulness in facilitating shared decision making regarding understanding the patient’s risk of stroke and whether or not to start AC therapy. Both patients and providers will review the app and complete multiple questionnaires about the usability and perceived usefulness of the mobile app in a clinical setting. We will also audio-record a subset of encounters to assess for evidence of shared decision making. Enrollment in the AFib 2gether shared decision-making study is still ongoing for both patients and providers. The first participant enrolled on November 22, 2019. Analysis and publishing of results are expected to be completed in spring 2021. The AFib 2gether app emerged from a desire to increase the ability of patients and providers to engage in shared decision making around understanding the risk of stroke and AC therapy. We anticipate that the AFib 2gether mobile app will facilitate patient discussion with their cardiologist and other providers. Additionally, we hope the study will help us identify barriers that providers face when placing patients on AC therapy. We aim to demonstrate the usability and perceived usefulness of the app with a future goal of testing the value of our approach in a larger sample of patients and providers at multiple medical centers across the country. ClinicalTrials.gov NCT04118270; https://clinicaltrials.gov/ct2/show/NCT04118270 DERR1-10.2196/21986
登录
查看更多内容
DOI：
10.1177/1076029620952550
发表时间：
2020-01
期刊：
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
影响因子：
--
作者：
Saeed H;Ovalle OG;Bokhary U;Jermihov A;Lepkowska K;Bauer V;Kuchta K;Wright M;Glosner S;Frazer M;Quintero A;Hlavacek P;Mardekian J;Tafur A;Metzl M;Saucedo J
通讯作者：
Saucedo J
影响因子：
3.7
作者：
Terhorst Y;Philippi P;Sander LB;Schultchen D;Paganini S;Bardus M;Santo K;Knitza J;Machado GC;Schoeppe S;Bauereiß N;Portenhauser A;Domhardt M;Walter B;Krusche M;Baumeister H;Messner EM
通讯作者：
Messner EM
影响因子：
7.3
作者：
DAVIS, FD
通讯作者：
DAVIS, FD
影响因子：
--
作者：
Elwyn, G;Edwards, A;Grol, R
通讯作者：
Grol, R
影响因子：
5.4
作者：
Kapoor A;Amroze A;Golden J;Crawford S;O'Day K;Elhag R;Nagy A;Lubitz SA;Saczynski JS;Mathew J;McManus DD
通讯作者：
McManus DD